Literature DB >> 17138820

CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features.

Kennosuke Karube1, Ying Guo, Junji Suzumiya, Yasuo Sugita, Yuko Nomura, Kohei Yamamoto, Kei Shimizu, Shirou Yoshida, Hideki Komatani, Morishige Takeshita, Masahiro Kikuchi, Naoya Nakamura, Osamu Takasu, Fumiko Arakawa, Hiroyuki Tagawa, Masao Seto, Koichi Ohshima.   

Abstract

CD10 and MUM1 are representative B cell differentiation markers. Follicular lymphoma (FL) is usually positive for CD10 and negative for MUM1. In this study, however, we compared 22 FLs with peculiar phenotype CD10-MUM1+ with 119 typical CD10+MUM1- FLs. All CD10-MUM1+ FL patients exhibited follicular structure with follicular dendritic meshwork, and a high rate of somatic hypermutation and ongoing mutation, similar to typical FL. However, CD10-MUM1+ FLs were encountered frequently in the elderly compared with CD10+MUM1- typical FLs (67.0 versus 58.7 years, P < .01), showed high grade (grade 3A or 3B) morphology (91% versus 17%, P < .001), diffuse proliferation (59% vs 19%, P < .001), and lacked BCL2/IGH translocation (5% versus 92.5%, P < .001), which is the most characteristic aberration in FL, and 88% showed BCL6 gene abnormalities (translocation or amplification). Our results indicate that CD10-MUM1+ FL is different from typical FL with respect to biologic and clinical features.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17138820     DOI: 10.1182/blood-2006-09-045989

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

1.  Follicular lymphomas: a tapestry of common and contrasting threads.

Authors:  Elaine S Jaffe
Journal:  Haematologica       Date:  2013-08       Impact factor: 9.941

Review 2.  Transformation of follicular lymphoma.

Authors:  Izidore S Lossos; Randy D Gascoyne
Journal:  Best Pract Res Clin Haematol       Date:  2011-05-06       Impact factor: 3.020

3.  Follicular lymphoma grade 3B: is it a real disease?

Authors:  Nancy Lee Harris; Philip Kluin
Journal:  Haematologica       Date:  2011-09       Impact factor: 9.941

Review 4.  The heterogeneity of follicular lymphomas: from early development to transformation.

Authors:  Luc Xerri; Stephan Dirnhofer; Leticia Quintanilla-Martinez; Birgitta Sander; John K C Chan; Elias Campo; Steven H Swerdlow; German Ott
Journal:  Virchows Arch       Date:  2015-10-19       Impact factor: 4.064

5.  CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases.

Authors:  Yu Li; Shimin Hu; Zhuang Zuo; Ming Hong; Pei Lin; Shaoying Li; Sergej Konoplev; Zhen Wang; Joseph D Khoury; Ken H Young; L Jeffrey Medeiros; C Cameron Yin
Journal:  Mod Pathol       Date:  2015-03-06       Impact factor: 7.842

Review 6.  The follicular lymphoma microenvironment: From tumor cell to host immunity.

Authors:  Antonio Martinez; Joaquim Carreras; Elias Campo
Journal:  Curr Hematol Malig Rep       Date:  2008-10       Impact factor: 3.952

7.  Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles.

Authors:  Heike Horn; Christopher Schmelter; Ellen Leich; Itziar Salaverria; Tiemo Katzenberger; M Michaela Ott; Jörg Kalla; Monica Romero; Reiner Siebert; Andreas Rosenwald; German Ott
Journal:  Haematologica       Date:  2011-06-09       Impact factor: 9.941

Review 8.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

9.  Nodal Follicular Lymphomas: A Clinicopathological Study from a Tertiary Care Centre in South India.

Authors:  Divya Supari; Anuradha Ananthamurthy
Journal:  Indian J Hematol Blood Transfus       Date:  2015-11-02       Impact factor: 0.900

10.  Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study.

Authors:  J W Sweetenham; B Goldman; M L LeBlanc; J R Cook; R R Tubbs; O W Press; D G Maloney; R I Fisher; L M Rimsza; R M Braziel; E D Hsi
Journal:  Ann Oncol       Date:  2009-10-29       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.